CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy

Standard radiation therapy for patients undergoing primary chemosensitized radiation for carcinomas of the cervix usually consists of external beam radiation followed by an intracavitary brachytherapy boost. On occasion, the brachytherapy boost cannot be performed due to unfavorable anatomy or because of coexisting medical conditions. We examined the safety and efficacy of using CyberKnife stereotactic body radiotherapy (SBRT) as a boost to the cervix after external beam radiation in those patients unable to have brachytherapy to give a more effective dose to the cervix than with conventional external beam radiation alone. Six consecutive patients with anatomic or medical conditions precluding a tandem and ovoid boost were treated with combined external beam radiation and CyberKnife boost to the cervix. Five patients received 45 Gy to the pelvis with serial intensity-modulated radiation therapy boost to the uterus and cervix to a dose of 61.2 Gy. These five patients received an SBRT boost to the cervix to a dose of 20 Gy in five fractions of 4 Gy each. One patient was treated to the pelvis to a dose of 45 Gy with an external beam boost to the uterus and cervix to a dose of 50.4 Gy. This patient received an SBRT boost to the cervix to a dose of 19.5 Gy in three fractions of 6.5 Gy. Five percent volumes of the bladder and rectum were kept to ≤75 Gy in all patients (i.e., V75 Gy ≤ 5%). All of the patients remain locally controlled with no evidence of disease following treatment. Grade 1 diarrhea occurred in 4/6 patients during the conventional external beam radiation. There has been no grade 3 or 4 rectal or bladder toxicity. There were no toxicities observed following SBRT boost. At a median follow-up of 14 months, CyberKnife radiosurgical boost is well tolerated and efficacious in providing a boost to patients with cervix cancer who are unable to undergo brachytherapy boost. Further follow-up is required to see if these results remain durable.

[1]  C. Yashar,et al.  Evaluation of intra- and inter-fraction movement of the cervix during intensity modulated radiation therapy. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  S. Hsiao,et al.  Should helical tomotherapy replace brachytherapy for cervical cancer? Case report , 2010, BMC Cancer.

[3]  R. Miralbell,et al.  Hypofractionated Extracranial Stereotactic Radiotherapy Boost for Gynecologic Tumors: A Promising Alternative to High-Dose Rate Brachytherapy , 2010, Technology in cancer research & treatment.

[4]  C. Maurer,et al.  The CyberKnife® Robotic Radiosurgery System in 2010 , 2010, Technology in cancer research & treatment.

[5]  Mirit I. Aladjem,et al.  This is an openaccess article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited , 2022 .

[6]  Alexandra Taylor,et al.  An assessment of interfractional uterine and cervical motion: implications for radiotherapy target volume definition in gynaecological cancer. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  J. Livsey,et al.  External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed. , 2008, International journal of radiation oncology, biology, physics.

[8]  Haoran Jin,et al.  Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. , 2008, International journal of radiation oncology, biology, physics.

[9]  M. Bidmead,et al.  Movement of the cervix in after-loading brachytherapy: implications for designing external-beam radiotherapy boost fields. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  R. Miralbell,et al.  Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? , 2005, International journal of radiation oncology, biology, physics.

[11]  Mitchell Morris,et al.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Quinn CyberKnife: a robotic radiosurgery system. , 2002, Clinical journal of oncology nursing.

[13]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[14]  P. Grigsby,et al.  Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. , 1995, International journal of radiation oncology, biology, physics.

[15]  J. Fowler,et al.  The adverse effect of treatment prolongation in cervical carcinoma. , 1995, International journal of radiation oncology, biology, physics.

[16]  A. Gerbaulet,et al.  Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. , 1993, International journal of radiation oncology, biology, physics.

[17]  A. Fyles,et al.  The effect of treatment duration in the local control of cervix cancer. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  J. Johnsson Squamous cell carcinoma of the uterine cervix. , 1977, Acta radiologica: therapy, physics, biology.

[19]  A. G. Foraker,et al.  Squamous-cell carcinoma of the uterine cervix; a histochemical review. , 1958, American journal of obstetrics and gynecology.

[20]  T. Pajak,et al.  The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. , 1993, International journal of radiation oncology, biology, physics.